Viewing Study NCT05442060


Ignite Creation Date: 2025-12-25 @ 2:05 AM
Ignite Modification Date: 2025-12-27 @ 11:04 PM
Study NCT ID: NCT05442060
Status: RECRUITING
Last Update Posted: 2025-08-03
First Post: 2022-06-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor: OBI Pharma, Inc
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module